X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharoptosis.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: LEV102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Product Name: Rhofade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $7.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 21, 2022
Details:
Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Afrin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: RVL Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 30, 2022
Details:
The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Athyrium Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 04, 2022
Details:
Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Product Name: Rhofade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novan
Deal Size: $51.0 million Upfront Cash: $27.5 million
Deal Type: Acquisition March 11, 2022
Details:
The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Athyrium Capital Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 07, 2021
Details:
Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alora Pharmaceuticals
Deal Size: $170.0 million Upfront Cash: $110.0 million
Deal Type: Divestment June 25, 2021
Details:
Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: RVL Pharmaceuticals
Deal Size: $89.0 million Upfront Cash: $25.0 million
Deal Type: Licensing Agreement July 28, 2020
Details:
U.S FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can limit field of vision.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Upneeq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
